Advanced searches left 3/3

Deoxyribonucleic Acid - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 11 May 2022

* If you want to update the article please login/register

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

To determine whether omitting adjuvant CDDP and 5-FU will result in non-inferior overall survival as compared to those patients receiving adjuvant CDDP and 5-FU chemotherapy. OUTLINE: During IMRT, patients receive low-dose cisplatin intravenously for 6. 5 weeks every week and receive low-dose cisplatin intravenously over 30-60 minutes once a week. PHASE II: Patients with detectable EBV DNA from pre-treatment testing are assigned to 1 of two treatment arms. Patients are given a PF regimen consisting of cisplatin IV over 60-120 minutes and fluorouracil IV over 96 hours per week, beginning at least four weeks after IMRT's completion. Patients are treated by a GT programme comprising paclitaxel IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 at least four weeks after completion of IMRT. PHASE III: Patients with undetectable EBV DNA from pre-treatment samples are randomized to one of two treatment arms.

Source link: https://clinicaltrials.gov/ct2/show/NCT02135042

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions